EPCAM and hepatocellular carcinoma: Treatment with the BMP-receptor inhibitor LDN-212854, which inhibits both ALK1 and ALK2, suppressed HCC tumor growth by repressing ID1 and EpCAM in vivo in a xenograft mouse model of HCC [59].